TY  - JOUR
A1  - Agarwal, Shiwani
A1  - Weidner, Tatjana
A1  - Thalheimer, Frederic Bastian
A1  - Buchholz, Christian
T1  - In vivo generated human CAR T cells eradicate tumor cells
T2  - OncoImmunology
N2  - Chimeric antigen receptor (CAR) T cells are in prime focus of current research in cancer immunotherapy. Facilitating CAR T cell generation is among the top goals. We have recently demonstrated direct in vivo generation of human CD19-CAR T cells by targeting CD8+ cells using lentiviral vectors (LVs). The anti-tumor potency of in vivo generated CAR T cells was assessed in human PBMC-transplanted NSG mice carrying i.v. injected CD19+ Nalm-6 tumor cells. A single injection of CD8-targeted LV delivering CD19-CAR was sufficient to completely eliminate the tumor cells from bone marrow and spleen, whereas control animals contained high levels of CD19+ cells. Tumor elimination was due to in vivo generated CAR+ cells. Notably, these were not only composed of T lymphocytes but also included CAR+ natural killer cells (NK and NKT). This is the first demonstration of tumor elimination by in vivo generated human CAR T cells.
KW  - Cell therapy
KW  - CAR T cells
KW  - in vivo gene delivery
KW  - receptor targeting
KW  - T-cell targeting
Y1  - 2019
UR  - http://publikationen.ub.uni-frankfurt.de/frontdoor/index/index/docId/54433
UR  - https://nbn-resolving.org/urn:nbn:de:hebis:30:3-544335
SN  - 2162-402X
SN  - 2162-4011
N1  - This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.
VL  - 8
IS  - 12, e1671761
SP  - e1671761-1
EP  - e1671761-7
PB  - Taylor & Franics
CY  - Abingdon
ER  -